Abstract: Provided herein are methods and computer-readable storage media related to cell-free DNA and uses thereof to determine risk of a condition, such as transplant rejection or cancer, in a subject.
Abstract: Provided herein are methods of reducing or eliminating undifferentiated pluripotent stem cells, where the methods comprise contacting an effective amount of a compound to a heterogeneous cell population or sample comprising or suspected of comprising differentiated cell types and undifferentiated pluripotent stem cells, whereby the contacting selectively reduces or eliminates undifferentiated pluripotent stem cells from the cell population or sample. Also provided are methods for obtaining a population of stem cell-derived cell types substantially free of undifferentiated pluripotent stem cells as well as isolated populations of such of stem cell-derived cell types.
Type:
Grant
Filed:
January 21, 2015
Date of Patent:
June 11, 2019
Assignee:
The Medical College of Wisconsin, Inc.
Inventors:
Rebekah L. Gundry, Kenneth R. Boheler, Erin M. Kropp
Abstract: Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition in a subject.
Abstract: A magnetic resonance imaging (MRI) system can include a magnetic resonance imaging (MRI) scanner, having a plurality of radio frequency (RF) receivers, and a processor. The MRI scanner can perform a full field of view (fFOV) scan on an anatomy area including an implant to acquire first multi-spectral MRI data associated with a plurality of frequency bins. The processor can generate, for each pair of a single RF receiver and a single frequency bin, a respective spectral sensitivity map using at least a portion of the fFOV multi-spectral MRI data. The MRI scanner can perform a reduced FOV (rFOV) scan to acquire second multi-spectral MRI data associated with the plurality of frequency bins. The processor can reconstruct one or more MRI images according to the rFOV using the rFOV multi-spectral MRI data and the spectral sensitivity maps.
Type:
Application
Filed:
April 24, 2017
Publication date:
May 23, 2019
Applicant:
Medical College of Wisconsin
Inventors:
Kevin Matthew Koch, Andrew Scott Nencka
Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a pregnant subject with the non-native nucleic acids being fetal specific. The methods and compositions provided herein can be used to determine risk of a condition, such as a fetal condition, in a pregnant subject.
Abstract: Systems and methods directed to adaptive radiotherapy planning are provided. In some aspects, provided system and method include producing synthetic images from magnetic resonance data using relaxometry maps. The method includes applying corrections to the data and generating relaxometry maps therefrom. In other aspects, a method for adapting a radiotherapy plan is provided. The method includes determining an objective function based on dose gradients from an initial dose distribution, and generating an optimized plan based on updated images, using aperture morphing and gradient maintenance algorithms without need for organ-at-risk contouring.
Type:
Grant
Filed:
June 25, 2018
Date of Patent:
May 21, 2019
Assignee:
The Medical College of Wisconsin, Inc.
Inventors:
X. Allen Li, Eric S. Paulson, Ergun Ahunbay, Cun-geng Yang, Vern Hart
Abstract: Provided herein are therapeutic agents having specificity for human CLPTM1 L polypeptide, including therapeutic agents comprising one or more CLPTM1 L-targeting agents, compositions comprising such therapeutic agents, and methods of using such compositions for treating or preventing a cancer, pre-cancerous lesion, or other disease condition associated with CLPTM1 L protein dysfunction (e.g., pathogenic production, modification, or function).
Abstract: A catheter assembly includes an elongated catheter shaft, a magnetic sensor, and one or more wires. The elongated catheter shaft has a shaft proximal end and a shaft distal end, and the magnetic sensor includes a coil having a coil proximal end and a coil distal end that is situated toward or at the shaft distal end. The one or more wires extend through the elongated catheter shaft and are situated adjacent the magnetic sensor. Each of the one or more wires is electrically coupled to the coil at the coil distal end.
Type:
Application
Filed:
July 1, 2016
Publication date:
October 18, 2018
Applicants:
The Medical College of Wisconsin, Inc., Johann Wolfgang Goethe-Universität Frankfurt
Inventors:
John David Imig, Md. Abdul Hye Khan, Eugen Proschak, Rene Blocher
Abstract: A method for correcting one or more artifacts within a multi-spectral magnetic resonance image is provided. The method includes acquiring a plurality of spectral bins each including a plurality of voxels and corresponding to a different frequency of MR signals emitted by an imaged object. The plurality of voxels of each spectral bin correspond to the frequency of the spectral bin so as to define a spatial coverage of the spectral bin. The method further includes expanding each spectral bin by increasing the spatial coverage of the spectral bin, and generating the multi-spectral magnetic resonance image based at least in part on the expanded spectral bins.
Type:
Application
Filed:
April 6, 2018
Publication date:
October 11, 2018
Applicants:
GENERAL ELECTRIC COMPANY, MEDICAL COLLEGE OF WISCONSIN
Inventors:
SURYANARAYANAN SIVARAN KAUSHIK, KEVIN MATTHEW KOCH
Abstract: Systems and methods directed to adaptive radiotherapy planning are provided. In some aspects, provided system and method include producing synthetic images from magnetic resonance data using relaxometry maps. The method includes applying corrections to the data and generating relaxometry maps therefrom. In other aspects, a method for adapting a radiotherapy plan is provided. The method includes determining an objective function based on dose gradients from an initial dose distribution, and generating an optimized plan based on updated images, using aperture morphing and gradient maintenance algorithms without need for organ-at-risk contouring.
Type:
Grant
Filed:
December 30, 2014
Date of Patent:
July 24, 2018
Assignee:
The Medical College of Wisconsin, Inc.
Inventors:
X. Allen Li, Eric S. Paulson, Ergun Ahunbay, Cun-geng Yang, Vern Hart
Abstract: The present invention provides a novel modified BoNT/E catalytic domain and methods of use thereof. In one embodiment, the light chain residue 224, or a residue corresponding to residue 224, of the modified BoNT/E catalytic domain has been altered to be aspartic acid or glutamic acid. The modified catalytic domain cleaves SNAP23 but does not cleave SNAP29 or SNAP47, providing novel methods of treating diseases including without limitation, asthma, CF, chronic obstructive pulmonary, gastric acid efflux and inflammation, immune disorders with a cytokine component or cancers with a cytokine component.
Abstract: This invention relates to methods and compositions for assessing an amount of non-native nucleic acids in a sample, such as from a subject. The methods and compositions provided herein can be used to determine risk of a condition, such as transplant rejection, in subject.
Type:
Application
Filed:
April 29, 2016
Publication date:
May 24, 2018
Applicant:
Medical College of Wisconsin, Inc.
Inventors:
Aoy Tomita MITCHELL, Michael MITCHELL, Karl STAMM
Abstract: The present invention provides modified metformin compounds, particularly mito-metformin compounds, and pharmaceutical compositions thereof. Methods of using the compounds to provide neuroprotection and in the treatment and/or prevention of neurodegenerative diseases are also described.
Type:
Grant
Filed:
October 14, 2016
Date of Patent:
May 1, 2018
Assignees:
Iowa State University Research Foundation, Inc., The Medical College of Wisconsin, Inc.
Abstract: The present invention provides a CXCL121 peptide engineered to resist peptide-induced dimerization by maintaining steric repulsion of the chemokine helix, pharmaceutical compositions thereof, and methods of using said dimer in the treatment of cancer, inflammatory disorders, autoimmune disease, and HIV/AIDS.
Type:
Grant
Filed:
June 11, 2015
Date of Patent:
March 6, 2018
Assignee:
The Medical College of Wisconsin, Inc.
Inventors:
Brian Volkman, Joshua Ziarek, Christopher Veldkamp, Francis Peterson
Abstract: A method for highly accelerated projection imaging (“HAPI”) is provided. In this method, conventional linear gradients are used to obtain coil sensitivity-weighted projections of the object being imaged. Only a relatively small number of projections, such as sixteen or less, of the object are required to reconstruct a two-dimensional image of the object, unlike conventional projection imaging techniques. The relationship between the voxel values of the imaged object and the coil sensitivity-weighted projections is formulated as a linear system of equations and the reconstructed images are obtained by solving this matrix equation. This method advantageously allows higher acceleration rates compared to echo planar imaging (“EPI”) with SENSE or GRAPPA acceleration. Moreover, the method does not require any additional or specialized hardware because hardware in conventional MRI scanners is adequate to implement the method.
Type:
Grant
Filed:
May 31, 2013
Date of Patent:
January 30, 2018
Assignee:
The Medical College of Wisconsin
Inventors:
Lutfi Tugan Muftuler, Ali Ersoz, Volkan Emre Arpinar
Abstract: This invention relates to a system that adaptively compensates for subject motion in real-time in an imaging system. An object orientation marker (30), preferably a retro-grate reflector (RGR), is placed on the head or other body organ of interest of a patient (P) during a scan, such as an MRI scan. The marker (30) makes it possible to measure the six degrees of freedom (x, y, and z-translations, and pitch, yaw, and roll), or “pose”, required to track motion of the organ of interest. A detector, preferably a camera (40), observes the marker (30) and continuously extracts its pose. The pose from the camera (40) is sent to the scanner (120) via an RGR processing computer (50) and a scanner control and processing computer (100), allowing for continuous correction of scan planes and position (in real-time) for motion of the patient (P).
Type:
Grant
Filed:
August 17, 2015
Date of Patent:
January 16, 2018
Assignees:
The Queen's Medical Center, The University of Hawaii, The Medical College of Wisconsin, Inc., UWM Research Foundation, Inc.
Inventors:
Thomas Michael Ernst, Thomas Edmund Prieto, Brian Stewart Randall Armstrong
Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.
Type:
Grant
Filed:
April 22, 2015
Date of Patent:
October 3, 2017
Assignees:
Blood Center Research Foundation, The Medical College of Wisconsin, Inc.
Abstract: Certain embodiments of the present invention are directed to therapeutic intervention in patients with eye-length-related disorders to prevent, ameliorate, or reverse the effects of the eye-length-related disorders. Embodiments of the present invention include methods for early recognition of patients with eye-length-related disorders, therapeutic methods for inhibiting further degradation of vision in patients with eye-length-eye-length-related disorders, reversing, when possible, eye-length-related disorders, and preventing eye-length-related disorders. Additional embodiments of the present invention are directed to particular devices used in therapeutic intervention in patients with eye-length-related disorders.
Abstract: Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ib? having a combination of G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ib? and von Willebrand factor.
Type:
Grant
Filed:
September 15, 2014
Date of Patent:
June 13, 2017
Assignees:
BLOOD CENTER RESEARCH FOUNDATION, THE MEDICAL COLLEGE OF WISCONSIN, INC.